• Sat. Jan 28th, 2023

Black Diamond Therapeutics And 2 Other Penny Stocks Insiders Are Aggressively Buying – Applied Blockchain (NASDAQ:APLD), Black Diamond Therapeutic (NASDAQ:BDTX)

ByLisa Levin

Nov 1, 2022
Black Diamond Therapeutics And 2 Other Penny Stocks Insiders Are Aggressively Buying - Applied Blockchain (NASDAQ:APLD), Black Diamond Therapeutic (NASDAQ:BDTX)

The Dow Jones closed lower by more than 100 points on Monday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.3

Blue Star Foods

  • The Trade: Blue Star Foods Corp. BSFC Director Trond K Ringstad bought a total of 5,199 shares at an average price of $0.95. To acquire these shares, it cost around $4.95 thousand.
  • What’s Happening: Blue Star Foods, during September, signed a one-year extension to its multi-year supply contract with Sysco Corp.
  • What Blue Star Foods Does: Blue Star Foods Corp is an international seafood company. It imports, packages, and sells refrigerated pasteurized crab meat, and other premium seafood products.

Applied Blockchain

  • The Trade: Applied Blockchain, Inc. APLD CEO, Chairman Wes Cummins acquired a total of 40,000 shares at an average price of $2.23. The insider spent around $89.2 thousand to buy those shares.
  • What’s Happening: Applied Blockchain, last month, posted adjusted loss of $0.04 per share.
  • What Applied Blockchain Does: Applied Blockchain Inc is an Ethereum and altcoin mining company.

Wall Street’s Most Accurate Analysts Reshuffled Their Best Oil & Gas Picks, Here They Are

Don’t forget to check out our premarket coverage here .

Black Diamond Therapeutics

  • The Trade: Black Diamond Therapeutics, Inc. BDTX 10% owner BB Biotech AG acquired a total of 364,652 shares at an average price of $2.02. To acquire these shares, it cost around $736.19 thousand.
  • What’s Happening: Black Diamond Therapeutics, during August, posted a Q2 loss of $0.63 per share.
  • What Black Diamond Therapeutics Does: Black Diamond Therapeutics Inc is a precision oncology medicine company.



Image and article originally from www.benzinga.com. Read the original article here.